Sign in

NCT06242119Recruiting

Clinical Application of the J-PET Scanner Prototype

Clinical Use of a J-PET Scanner Prototype Made of Plastic Scintilators

Source: ClinicalTrials.gov · Last updated 19 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Positron emission tomography (PET), an advanced diagnostic imaging technique, exploits the annihilation of positrons (e+) to delineate pathological alterations within diseased tissues. Integral to PET scanners are detector systems that transform gamma photons into fluorescent photons, thereby gleaning insights into the energy, time, and spatial distribution of gamma photons emanating from positron-emitting radiopharmaceuticals. Conventional PET scanners, bear a significant financial burden primarily due to their reliance on LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. The exorbitant cost and limited availability of these crystal scintillators impede the widespread adoption of PET scanners. In a departure from conventional PET technology, the prototype J-PET scanner employed in this trial employs plastic scintillators, characterized by unique physical properties. This prototype is further equipped with bespoke software enabling three-photon imaging based on the annihilation of ortho-positronium (o-Ps) generated within diseased tissue. This study delves into the clinical applicability of PET scanners employing plastic scintillators, particularly investigating the feasibility of PET imaging using plastic scintillators where gamma quanta interact by mechanisms other than the photoelectric effect. Furthermore, this study endeavors to contemporaneously acquire and analyze data related to the lifetime of ortho-positronium (o-P) atoms emanating from routine radiopharmaceuticals. Additionally, it seeks to validate the utilization of a novel diagnostic indicator, termed the \"positron biomarker,\" through a prospective study, comparing its efficacy to conventional diagnostic PET scanning methodologies.

Status (registry)
Recruiting
Study type
Observational
Enrollment
25 (estimated)
First submitted
27 Jan 2024
Start date
7 Mar 2024
Primary completion date
31 Aug 2024
Lead sponsor
Jagiellonian University
NCT number
NCT06242119

What you commit to

  • Study type: Observational
  • Planned participants: 25
  • From 7 Mar 2024 to the primary completion date, 31 Aug 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • People with a previously diagnosed allergy to radiopharmaceuticals

Age

  • Age under 18 years

Other

  • Pregnant women, breastfeeding women
  • Lack of cooperation with the patient
  • Lack of informed consent to participate in the study

Who the study is looking for

  • The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the entire body.
  • Age over 18 years
  • Informed, voluntary consent to participate in the study

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow
Coordinator of this site? Confirm its status
KrakowPolandRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.